Blockade of Activin Receptor IIB Protects Arthritis Pathogenesis by Non‐Amplification of Activin A‐ACVR2B‐NOX4 Axis Pathway
Advanced Science · 2023
DOI: 10.1002/advs.202205161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Jimin Jeon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Sungkyunkwan University, Suwon, 16419, Republic of Korea. Hauptthemen laut MEDLINE: Chondrocytes, Osteoarthritis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Research Council of Science & Technology (NST) of the Korean government (MSIT), National Research Foundation of Korea, Korea Healthcare Technology R&D project of the Korea Health Industry Development Institute.
Abstract (Originalsprache)
Although activin receptor IIB (ACVR2B) is emerging as a novel pathogenic receptor, its ligand and assembled components (or assembly) are totally unknown in the context of osteoarthritis (OA) pathogenesis. The present results suggest that upregulation of ACVR2B and its assembly could affect osteoarthritic cartilage destruction. It is shown that the ACVR2B ligand, activin A, regulates catabolic factor expression through ACVR2B in OA development. Activin A Tg mice (Col2a1‐ Inhba ) exhibit enhanced cartilage destruction, whereas heterozygous activin A KO mice ( Inhba +/− ) show protection from cartilage destruction. In silico analysis suggests that the Activin A‐ACVR2B axis is involved in Nox4‐dependent ROS production. Activin A Tg:Nox4 KO (Col2a1‐ Inhba:Nox4 −/− ) mice show inhibition of experimental OA pathogenesis. NOX4 directly binds to the C‐terminal binding site on ACVR2B‐ACVR1B and amplifies the pathogenic signal for cartilage destruction through SMAD2/3 signaling. Together, the findings reveal that the ACVR2B assembly, which comprises Activin A, ACVR2B, ACVR1B, Nox4, and AP‐1‐induced HIF‐2 α , accelerates OA development. Furthermore, it is shown that shRNA‐mediated ACVR2B knockdown or trapping ligands of ACVR2B abrogate OA development by competitively disrupting the ACVR2B‐Activin A interaction. These results suggest that the ACVR2B assembly is required to amplify osteoarthritic cartilage destruction and could be a potential therapeutic target in efforts to treat OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
- CIRNO, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
- Department of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.
- Department of Orthopaedic Surgery, Uijeongbu St. Mary's Hospital, The Catholic University of Korea College of Medicine, Uijeongbu, 11765, Republic of Korea.
- MicroCT Applications, 3rd floor, 11, Sumyeong-ro 1-gil, Gangseo-gu, Seoul, 07644, Republic of Korea.
- Department of Oral Biology, Yonsei University College of Dentistry, Seoul, 03722, Republic of Korea.
ORCID-Profile: Seong-Il Eyun, Siyoung Yang
Förderung
- the National Research Council of Science & Technology (NST) of the Korean government (MSIT)
- National Research Foundation of Korea
- Korea Healthcare Technology R&D project of the Korea Health Industry Development Institute
- KRIBB
- Korea Research Institute of Bioscience and Biotechnology
Zitieren
APA
Jeon, J., Lee, H., Jeon, M. S., Kim, S. J., Choi, C., Kim, K. W., Yang, D. J., Lee, S., Bae, Y. S., Choi, W. I., Jung, J., Eyun, S. I., & Yang, S. (2023). Blockade of Activin Receptor IIB Protects Arthritis Pathogenesis by Non‐Amplification of Activin A‐ACVR2B‐NOX4 Axis Pathway. Advanced Science. https://doi.org/10.1002/advs.202205161
Vancouver
Jeon J, Lee H, Jeon MS, Kim SJ, Choi C, Kim KW, et al. Blockade of Activin Receptor IIB Protects Arthritis Pathogenesis by Non‐Amplification of Activin A‐ACVR2B‐NOX4 Axis Pathway. Advanced Science. 2023. doi:10.1002/advs.202205161
BibTeX
@article{Jeon2023,
author = {Jeon, Jimin and Lee, Hyemi and Jeon, Min-Seung and Kim, Seok-Jung and Choi, Cham and Kim, Ki Woo and Yang, Dong Joo and Lee, Sangho and Bae, Yong-Soo and Choi, Won Il and Jung, Juyeon and Eyun, Seong-Il and Yang, Siyoung},
title = {Blockade of Activin Receptor IIB Protects Arthritis Pathogenesis by Non‐Amplification of Activin A‐ACVR2B‐NOX4 Axis Pathway},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202205161}
}
EUVIMED